ADMA Biologics Inc
Ticker(s):
ADMA
Country:
Sector & Industry:
Business Overview
ADMA Biologics, Inc., a commercial biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics. In addition, the company operates source plasma collection facilities, including collections of source plasma, procurement of raw materials and packaging materials, and the testing of finished drug products. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Contact & Other Information
Number of Employees:
685
Website:
,
,
ADMA Biologics, Inc. announced the Board’s approval of 2025 base salaries, 2024 cash bonuses, and annual incentive awards for key executives, as well as changes to director compensation.